PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19324269-2	2009	Recent studies confirmed that gefitinib interacted with the breast cancer resistance protein (BCRP) at submicromolar concentrations, whereas other multidrug transporters, including P-glycoprotein (P-gp), showed much lower reactivity toward gefitinib.	Gefitinib	30-39	phosphoglycolate phosphatase	Mus musculus	197-201	
19324269-2	2009	Recent studies confirmed that gefitinib interacted with the breast cancer resistance protein (BCRP) at submicromolar concentrations, whereas other multidrug transporters, including P-glycoprotein (P-gp), showed much lower reactivity toward gefitinib.	Gefitinib	240-249	phosphoglycolate phosphatase	Mus musculus	181-195	
19324269-2	2009	Recent studies confirmed that gefitinib interacted with the breast cancer resistance protein (BCRP) at submicromolar concentrations, whereas other multidrug transporters, including P-glycoprotein (P-gp), showed much lower reactivity toward gefitinib.	Gefitinib	240-249	phosphoglycolate phosphatase	Mus musculus	197-201	
19324269-8	2009	In conclusion, [(11)C]gefitinib is a promising PET tracer to evaluate the penetration of gefitinib into the brain by combined therapy with P-gp or BCRP modulators, and into brain tumors.	Gefitinib	22-31	phosphoglycolate phosphatase	Mus musculus	139-143	
19324269-8	2009	In conclusion, [(11)C]gefitinib is a promising PET tracer to evaluate the penetration of gefitinib into the brain by combined therapy with P-gp or BCRP modulators, and into brain tumors.	Gefitinib	89-98	phosphoglycolate phosphatase	Mus musculus	139-143	
20421331-0	2010	Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.	Gefitinib	16-25	phosphoglycolate phosphatase	Mus musculus	53-67	
16686369-10	2006	Since gefitinib is also an inhibitor of P-glycoprotein (P-gp), the impact of P-gp on sulfasalazine absorption in vivo was also examined.	Gefitinib	6-15	phosphoglycolate phosphatase	Mus musculus	40-54	
26264927-0	2015	PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.	Gefitinib	28-37	phosphoglycolate phosphatase	Mus musculus	60-64	
24011632-5	2013	RESULTS: The result showed that RE of gefitinib at the concentrations of 1 muM and 10 muM was 4.12 and 4.05, respectively, but significantly decreased to 1 and 1.35 after adding a P-glycoprotein (P-gp) inhibitor, cyclosporine A.	Gefitinib	38-47	phosphoglycolate phosphatase	Mus musculus	180-194	
24011632-5	2013	RESULTS: The result showed that RE of gefitinib at the concentrations of 1 muM and 10 muM was 4.12 and 4.05, respectively, but significantly decreased to 1 and 1.35 after adding a P-glycoprotein (P-gp) inhibitor, cyclosporine A.	Gefitinib	38-47	phosphoglycolate phosphatase	Mus musculus	196-200	
24011632-9	2013	CONCLUSION: Gefitinib is a P-gp substrate and has limited active BBB penetration.	Gefitinib	12-21	phosphoglycolate phosphatase	Mus musculus	27-31	
20421331-3	2010	In this study, we investigated the influence of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) on distribution of gefitinib to the central nervous system.	Gefitinib	133-142	phosphoglycolate phosphatase	Mus musculus	48-62	
20421331-3	2010	In this study, we investigated the influence of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) on distribution of gefitinib to the central nervous system.	Gefitinib	133-142	phosphoglycolate phosphatase	Mus musculus	64-68	
20421331-7	2010	The B/P ratio after oral administration increased significantly when gefitinib was coadministered with the dual P-gp and BCRP inhibitor elacridar.	Gefitinib	69-78	phosphoglycolate phosphatase	Mus musculus	112-116	
20421331-10	2010	These results show that brain distribution of gefitinib is restricted due to active efflux by P-gp and BCRP.	Gefitinib	46-55	phosphoglycolate phosphatase	Mus musculus	94-98	
19567673-7	2009	When gefitinib (200 mg/kg) was preadministered to inhibit Bcrp1 and P-gp, the vCSF-to-plasma ratio decreased to 1.29 +/- 0.09 in wild-type mice and increased to 1.13 +/- 0.13 in Mdr1a/b(-/-)Bcrp1(-/-) mice, whereas the ECF-to-plasma ratio increased to 0.74 +/- 0.14 in wild-type and 1.07 +/- 0.03 in Mdr1a/b(-/-)Bcrp1(-/-) mice.	Gefitinib	5-14	phosphoglycolate phosphatase	Mus musculus	68-72